Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
42.93
USD
|
-3.90%
|
|
-5.54%
|
-41.97%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13,616
|
21,070
|
13,412
|
8,797
|
13,379
|
7,922
|
-
|
-
|
Enterprise Value (EV)
1 |
14,120
|
20,573
|
14,561
|
10,401
|
14,916
|
9,650
|
9,237
|
8,803
|
P/E ratio
|
-145
x
|
-23.6
x
|
-22.4
x
|
-14
x
|
-65.5
x
|
-41
x
|
-437
x
|
56.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.5
x
|
14.1
x
|
7.59
x
|
4.22
x
|
5.35
x
|
2.8
x
|
2.46
x
|
2.19
x
|
EV / Revenue
|
16.1
x
|
13.8
x
|
8.24
x
|
4.99
x
|
5.97
x
|
3.41
x
|
2.87
x
|
2.43
x
|
EV / EBITDA
|
-117
x
|
789
x
|
-77.4
x
|
-72.5
x
|
68.2
x
|
29.2
x
|
18.3
x
|
13.1
x
|
EV / FCF
|
-49.2
x
|
285
x
|
-61.2
x
|
-23.7
x
|
467
x
|
386
x
|
27.5
x
|
16.4
x
|
FCF Yield
|
-2.03%
|
0.35%
|
-1.63%
|
-4.21%
|
0.21%
|
0.26%
|
3.64%
|
6.09%
|
Price to Book
|
5.97
x
|
7.09
x
|
3.94
x
|
2.87
x
|
4.27
x
|
2.38
x
|
2.17
x
|
1.92
x
|
Nbr of stocks (in thousands)
|
147,232
|
159,030
|
172,319
|
177,684
|
180,850
|
184,530
|
-
|
-
|
Reference price
2 |
92.48
|
132.5
|
77.83
|
49.51
|
73.98
|
42.93
|
42.93
|
42.93
|
Announcement Date
|
2/11/20
|
2/16/21
|
2/22/22
|
2/21/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
876.3
|
1,491
|
1,767
|
2,084
|
2,500
|
2,831
|
3,221
|
3,619
|
EBITDA
1 |
-120.7
|
26.08
|
-188.1
|
-143.4
|
218.8
|
330.5
|
505
|
669.9
|
EBIT
1 |
-170.9
|
-137.3
|
-599.4
|
-580
|
-259.1
|
-186.6
|
-12.14
|
123.7
|
Operating Margin
|
-19.51%
|
-9.21%
|
-33.92%
|
-27.83%
|
-10.36%
|
-6.59%
|
-0.38%
|
3.42%
|
Earnings before Tax (EBT)
1 |
-268.9
|
-857.1
|
-842.5
|
-632.6
|
-201.7
|
-179
|
-6.458
|
134.1
|
Net income
1 |
-83.99
|
-848.5
|
-595.6
|
-623.5
|
-204.1
|
-194.1
|
-25.66
|
118.2
|
Net margin
|
-9.59%
|
-56.9%
|
-33.71%
|
-29.91%
|
-8.17%
|
-6.86%
|
-0.8%
|
3.26%
|
EPS
2 |
-0.6400
|
-5.610
|
-3.480
|
-3.540
|
-1.130
|
-1.048
|
-0.0982
|
0.7549
|
Free Cash Flow
1 |
-286.8
|
72.13
|
-238
|
-438
|
31.93
|
25
|
336.3
|
536
|
FCF margin
|
-32.73%
|
4.84%
|
-13.47%
|
-21.02%
|
1.28%
|
0.88%
|
10.44%
|
14.81%
|
FCF Conversion (EBITDA)
|
-
|
276.6%
|
-
|
-
|
14.59%
|
7.56%
|
66.59%
|
80.01%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
453.64%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/11/20
|
2/16/21
|
2/22/22
|
2/21/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
473.8
|
486.6
|
521.6
|
523.1
|
553
|
602.4
|
622.1
|
628.3
|
646.9
|
637.5
|
691
|
731.4
|
771.7
|
734.4
|
787.5
|
EBITDA
1 |
-122.2
|
-89.82
|
-45.77
|
-13.04
|
4.934
|
45.91
|
66.85
|
56.28
|
49.71
|
39.2
|
68.63
|
104
|
121.8
|
80.8
|
121
|
EBIT
1 |
-222.2
|
-202.9
|
-162.1
|
-119.9
|
-95.34
|
-65.73
|
-72.1
|
-68.07
|
-70.93
|
-88.28
|
-57.11
|
-22.38
|
-8.308
|
-52.97
|
-11.43
|
Operating Margin
|
-46.9%
|
-41.71%
|
-31.08%
|
-22.93%
|
-17.24%
|
-10.91%
|
-11.59%
|
-10.83%
|
-10.97%
|
-13.85%
|
-8.26%
|
-3.06%
|
-1.08%
|
-7.21%
|
-1.45%
|
Earnings before Tax (EBT)
1 |
-224.9
|
-183
|
-167.8
|
-151.9
|
-129.9
|
-72.48
|
-79.92
|
1.043
|
-50.38
|
-108.4
|
-55.51
|
-19.16
|
-8.398
|
-53.83
|
-9.587
|
Net income
1 |
-220.6
|
-180.9
|
-166.1
|
-148.8
|
-127.7
|
-74.15
|
-81.03
|
0.794
|
-49.77
|
-110.2
|
-57.77
|
-24.36
|
-8.086
|
-53.52
|
-14.61
|
Net margin
|
-46.56%
|
-37.19%
|
-31.83%
|
-28.44%
|
-23.1%
|
-12.31%
|
-13.02%
|
0.13%
|
-7.69%
|
-17.29%
|
-8.36%
|
-3.33%
|
-1.05%
|
-7.29%
|
-1.86%
|
EPS
2 |
-1.280
|
-1.040
|
-0.9400
|
-0.8400
|
-0.7200
|
-0.4200
|
-0.4500
|
-
|
-0.2700
|
-0.6000
|
-0.3108
|
-0.1363
|
-0.0365
|
-0.2320
|
-0.0503
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/22/22
|
4/26/22
|
8/2/22
|
11/3/22
|
2/21/23
|
5/9/23
|
8/1/23
|
11/1/23
|
2/21/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
504
|
-
|
1,150
|
1,604
|
1,537
|
1,728
|
1,315
|
881
|
Net Cash position
1 |
-
|
497
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-4.176
x
|
-
|
-6.114
x
|
-11.19
x
|
7.024
x
|
5.229
x
|
2.604
x
|
1.316
x
|
Free Cash Flow
1 |
-287
|
72.1
|
-238
|
-438
|
31.9
|
25
|
336
|
536
|
ROE (net income / shareholders' equity)
|
-5.66%
|
-33.2%
|
-21.2%
|
-18.4%
|
-9.08%
|
-4.25%
|
0.54%
|
5.07%
|
ROA (Net income/ Total Assets)
|
-3.34%
|
-20.1%
|
-10.3%
|
-9.16%
|
-4.42%
|
-3.1%
|
-0.6%
|
1.2%
|
Assets
1 |
2,515
|
4,215
|
5,805
|
6,810
|
4,614
|
6,262
|
4,277
|
9,846
|
Book Value Per Share
2 |
15.50
|
18.70
|
19.80
|
17.30
|
17.30
|
18.00
|
19.70
|
22.40
|
Cash Flow per Share
2 |
-0.8800
|
0.8200
|
-0.6000
|
-1.270
|
0.8700
|
1.350
|
2.070
|
-
|
Capex
1 |
172
|
64.4
|
136
|
214
|
124
|
150
|
158
|
163
|
Capex / Sales
|
19.61%
|
4.31%
|
7.68%
|
10.29%
|
4.97%
|
5.31%
|
4.91%
|
4.51%
|
Announcement Date
|
2/11/20
|
2/16/21
|
2/22/22
|
2/21/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
42.93
USD Average target price
84.86
USD Spread / Average Target +97.67% Consensus |
1st Jan change
|
Capi.
|
---|
| -41.97% | 7.92B | | +5.99% | 3.51B | | -4.31% | 2.18B | | -21.69% | 1.97B | | -24.94% | 1.58B | | +31.45% | 1.14B | | +26.75% | 792M | | -9.83% | 690M | | -26.33% | 532M | | +3.38% | 303M |
Bio Diagnostics & Testing
|